Ad hoc-Mitteilungen

Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

| Aufrufe: 211

Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission 04-Jul-2022 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement.


Relief Therapeutics Files Amendment No. 4 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission

Geneva, Switzerland, July 4, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (“Relief”), announced today that it has filed Amendment No. 4 to its Registration Statement on Form 20‑F ("Registration Statement") with the U.S. Securities and Exchange Commission ("SEC"). The Registration Statement is intended to register Relief as a reporting company under the Securities Exchange Act of 1934. The Registration Statement has been filed as part of an ongoing program to convert Relief's Level 1 American Depositary Receipt ("ADR") program in the United States to a Level 2 ADR program, and is part of Relief's ongoing efforts to list its ADRs on the NASDAQ Stock Market. The NASDAQ listing will only occur after the Registration Statement has become effective, which is subject to a continuing review of the Registration Statement by the SEC, and the filing by Relief of a listing application with the NASDAQ (which has not yet occurred). There can be no assurance that the Registration Statement will become effective or that Relief will be successful in its efforts to list its ADRs to the NASDAQ Stock Market.

The filing of the Registration Statement is not part of an offering of securities. Therefore, Relief will receive no proceeds from its current ADR program.

Additional features: File: Ad hoc release
End of ad hoc announcement
Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Switzerland
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1389461
 
End of Announcement EQS News Service

1389461  04-Jul-2022 CET/CEST

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Kurs:
Relief Therap.
-10,54%
0,035 $  


Schließen

Lukrative Investment-Idee

Die nächste große Chance! Noch völlig unbekannt, aber unverzichtbar & unersetzlich! HELIUM bald in aller Munde
weiterlesen»